Patients may be asked to send laboratory, imaging and physician exam reports performed by their treating physician. Abbreviated Title: Personalized DC Vaccine Version Date: March 26, 2018 21 STUDY CALENDAR AssessmentsScreening/Baseline (prior to enrollment on treatment protocol)On-Study/Course of Treatment (1 vaccine = 1 cycle)Post-Treatment Follow-up Within 3 MonthsWithin 4 WeeksWithin 7 DaysDay 01Day 14 (±5 d)Day 28 (±5 d)Day 42 (±5 d)Day 56 (±5 d)Subsequent Follow-up Visits2 Informed consent3 Confirmation of diagnosis by NCI Lab of Pathology4 X Medical history5X Physical exam XX X X X X X X Performance score (ECOG)6XX X X X X X Vital signs7XX X X X X X ȕ-HCG pregnancy test8XX X X X X X Urinalysis9XX EKG XX Toxicity assessment XXX X X Laboratory Procedures Viral testing10X 1 Assessments (except TBNK and research samples) may be done within 7 days prior to the first vaccination on Day 0 . Lymphocyte phenotyping (TBNK) and research samples must be drawn wit hin 2 days prior to the first vaccination on Day 0. 2 The second follow-up evaluation will take place 1 month (± 5 da ys) after the first follow-up evaluation (Day 56). Subsequent f ollow-up evaluations will take place every 1-2 months for the first year, and then annually or as cl inically appropriate as determined by the PI. Patients may be se en more frequently as clinically indicated. Patients who are unable or unwilling to return for follow-up ev aluations may be followed via phone or email contact. Patients may be asked to send laboratory, imaging and physician exam reports performed by their treating physician. 3 The date of enrollment is the date the subject signs the writt en informed consent document. The patient will be consented and enrolled on this protocol once the patient has adequate leukapheresis material banked by the SB CP F and prior to administration of the first vaccine. 4 Confirmation of diagnosis of metastatic melanoma or epithelial cancer. Testing is permitted to be conducted at any time prior to enrollment.